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Autoantibodies directed to centromere 
protein F in a patient with BRCA1 gene 
mutation
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Abstract 
Background: Autoantibodies directed to centromere protein F were first reported in 1993 and their association with 
malignancy has been well documented.
Case: We present the case of a 48-year-old Caucasian female with a BRCA1 gene mutation associated with bilat-
eral breast cancer. Antinuclear autoantibody immunofluorescence performed for workup of possible inflammatory 
arthropathy showed a high titre cell cycle related nuclear speckled pattern, with subsequent confirmation by address-
able laser bead immunoassay of the target antigen as an immunodominant epitope at the C-terminus of centromere 
protein F.
Conclusion: Here we review the current literature on centromere protein F, its association with breast cancer and 
present the first case of this antibody being identified in a person with a BRCA1 gene mutation.
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Background
Centromere protein-F (CENP-F), also known at mitosin, 
is a ~400 kDa nuclear protein encoded by gene 1q32–41 
that associates with the centromere kinetochore com-
plex [1, 2]. It functions in a cell cycle manner, present as 
a nuclear matrix protein during interphase then redis-
tributing during early G2 of the cell cycle [1–4]. Since its 
discovery in 1993, a number of its functions have been 
elucidated, including involvement in centromere matura-
tion, regulation of metaphase checkpoint and ensuring 
appropriate orientation of chromosomes [4–9]. Further-
more, it is involved in the attenuation of histone meth-
ylation and negative regulation of activating transcription 
factor-4 (ATF4), a transcription factor important for 
stress proliferation and differentiation of cells [1, 10].
The expression of CENP-F in malignancies has been 
investigated over the past decade, with increased immu-
nohistochemical expression of CENP-F reported in 
breast, lung, ovarian and cervical cancer, non-Hodgkin 
lymphoma as well as squamous cell carcinoma of the 
oesophagus, oral mucosa and gingiva [7, 11]. Elevated 
expression of CENP-F has prognostic implications, cor-
relating with clinical and pathological parameters of 
poor prognosis in primary breast cancer including higher 
standardised uptake values on positron emission tomog-
raphy (PET) scan, shorter disease free survival times and 
higher recurrence rates [12, 13]. O’Brien et  al. investi-
gated the role of CENP-F in primary breast cancer with 
tissue microarrays in two cohorts and noted that CENP-
F mRNA overexpression (set at >10  % based on previ-
ous studies) was significantly associated with increased 
tumour size, higher tumour grade and oestrogen recep-
tor (ER) negativity [12].
Antibodies directed towards antigens expressed in 
tumour cells including CENP-F have been well described. 
Indirect immunofluorescence (IIF) of CENP-F autoan-
tibody positive serum using Hep-2 cell line shows a 
nuclear speckled pattern with cell cycle dependent fluo-
rescence and negative chromatin mass in mitosis [14]. 
Although present in less than 1 % of patients with malig-
nancy, anti-CENP-F antibodies have a positive predictive 
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value of approximately 50 % for cancer [14–16]. Further-
more, there is evidence to suggest that the appearance of 
these antibodies may be seen during progression from 
benign to malignant processes, as was demonstrated 
in two patients peri transition from chronic hepatitis to 
hepatocellular carcinoma as well as in oral leukoplakia, a 
premalignant lesion of the oral mucosa [17–19].
Previously, anti-CENP-F antibodies have been detected 
using radioimmunoassay, immunoblotting with native 
recombinant antigens or enzyme linked immunosorbent 
assay [16]. A more recent development has employed an 
addressable laser bead immunoassay (ALBIA) based on 
the two principal immunogenic epitopes of CENP-F, pep-
tides F1 and F4 [14, 20, 21]. Interestingly, half of patients 
who tested positive for CENP-F using this method did 
not have the corresponding typical IIF pattern, suggest-
ing that IIF may be an insensitive screening method for 
this autoantibody, and that the incidence in patients with 
malignancy may indeed be more than 1 %.
The potential therapeutic benefit of detecting increased 
expression of CENP-F, or autoantibodies directed 
towards it, has been studied with the use medications 
such as zoledronic acid that target farnesyl diphosphate 
synthase [22]. CENP-F is a farnesylated protein and inhi-
bition of farnesylation leads to loss of CENP-F from the 
kinetochore and subsequent inactivation [22]. Farnesyl 
transferase inhibitors (FTIs) are a novel class of chemo-
therapeutic agents showing promise in the treatment of 
cancer [23]. Although thought to act mainly by its down-
stream effects on Ras, the actions of FTIs are not Ras-
specific and it is possible that the lack of farnesylation 
of other proteins, including CENP-F, may have a role in 
their success [12, 23–26].
To date, neither the over expression of CENP-F nor 
the detection of autoantibodies directed towards it have 
been described in a BRCA1 mutation positive popula-
tion. BRCA1, a tumour suppressor gene located on chro-
mosome 17, is mutated at high frequency in hereditary 
breast and ovarian cancers. The role of CENP-F in patho-
genesis of disease in this population, and the theoretical 
benefit of FTIs, has not yet been explored.
Case report
A 48-year-old Caucasian female was referred to a rheu-
matologist experiencing fatigue and widespread joint 
pain, worse in the morning and improving with activity, 
associated with new onset psoriasis. The results from a 
number of investigations performed 3  months prior to 
review include C-reactive protein 16 (n < 5 mg/L), eryth-
rocyte sedimentation rate 57 (n < 20 mm/h), and a nega-
tive rheumatoid factor and HLA-B27. An antinuclear 
antibody (ANA) performed at this time was reported as 
positive at a titre of 1:1280 with a speckled pattern, but 
antibodies to extractable nuclear antigens (ENA) and ds-
DNA were negative.
The ANA was repeated by IIF on the HEp-2000 Fluo-
rescent ANA-Ro60 Test System according to the manu-
facturer’s directions (Immuno Concepts, Sacramento, 
CA). The sample was screened at a dilution of 1:160 and 
sequentially diluted at titres 1:320, 1:640 and 1:1280 with 
the result recorded as the highest dilution ANA pattern 
remained discernible. The repeat ANA showed a nuclear 
speckled-II (NSII) pattern [27] at a titre of 1:1280 (Fig. 1). 
The NSpII pattern is a cell cycle dependent pattern sug-
gestive of CENP-F autoantibodies, typically character-
ised by strong centromere staining in prometaphase and 
metaphase, variable nuclear staining in interphase and 
weak staining in anaphase. Approximately 60  % of sera 
demonstrating this pattern also have staining of the mid-
body during telophase (Fritzler unpublished data). As 
there were no commercially available assays identifying 
Fig. 1 Cell cycle dependent pattern characterised by strong cen-
tromere staining in prophase (A) and prometaphase (A, B), variable 
nuclear staining in interphase (C), weak staining in metaphase (D) 
and staining of midbody during anaphase and early telophase (E). 
Hep-2000 Fluorecent ANA-Ro Test System (Immuno Concepts), 1:160, 
40× magnification
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this specificity, the sample was sent to the Mitogen 
Advanced Diagnostics Laboratory at the University of 
Calgary where an ALBIA was developed for this purpose 
using protocols as previously described [28]. This process 
involved covalent coupling CENP-F peptides F1 and F4 
to separate dye laden addressable microbeads and pipet-
ting both into a single microtiter well, with the subse-
quent addition of both serum and fluorochrome-coupled 
secondary antibody. The sample was then processed by a 
Luminex 200 analyser (Luminex Corp., Austin, TX). The 
two lasers in the instrument and flow cytometric princi-
ples allowed determination of both specificity and quan-
tification of autoantibody, with results expressed as mean 
fluorescence units (MFU) of the fluorochrome-coupled 
secondary antibody [28]. Antibodies to both epitopes 
were detected in the patient’s serum, with a low positive 
reading for p-F1 and a high positive for p-F4.
Given the association of this autoantibody specificity 
with malignancy, further history was sought from the 
referring clinician. At age 45, the patient was diagnosed 
with stage III left sided breast cancer and underwent 
mastectomy, axillary clearance and combined adjuvant 
chemotherapy and radiotherapy. Her post-treatment 
course was complicated by melanoma in the field of radi-
ation. She underwent genetic testing for risk stratifica-
tion and was noted to be BRCA1 positive. Approximately 
1  year after the initial diagnosis she underwent a pro-
phylactic bilateral salpingo-oophorectomy, with two foci 
of severe dysplasia seen in the right fallopian tube. Six 
months later, she was noted to have lymphadenopathy in 
the contralateral axillae that was biopsied and positive for 
adenocarcinoma, and subsequently had a right mastec-
tomy and axillary clearance.
Discussion
There have been no reports of antibodies to CENP-F 
expressed in patients who are BRCA1 gene mutation posi-
tive. Literature on the association of CENP-F immuno-
histochemical staining in breast cancer of patients with 
BRCA1 mutation is also lacking. There are a number of 
potential reasons for this, including the questionable 
value of detecting this marker of high risk in a population 
that will already undergo rigorous monitoring for recur-
rence post diagnosis. Furthermore, the genetic heteroge-
neity in breast cancer may lead to the presumption that 
the co-existence of these autoantibodies may indeed be 
coincidental, and antibodies to multiple autoantigens may 
be detected if tested. In an unselected breast cancer popu-
lation, Fritzler et al. documented 7/190 (3.7 %) of breast 
cancer patients testing positive for CENP-F autoantibod-
ies [14]. The rate of positivity in the BRCA1 population 
is unclear, and cohort studies may help clarify this. The 
implication of this information, however, is less certain.
There is little information on the use of these autoan-
tibodies as a marker of disease remission or recurrence. 
One report identified a single patient with breast can-
cer and undifferentiated connective tissue disease and 
tracked the mean fluorescence units (MFU) of autoan-
tibodies targeting both p-F1 and p-F4 over time [14]. 
The relationship between autoantibody levels, epitope 
specificity and the clinical picture was not clear. As 
these autoantibodies are unlikely to be singularly 
causal, we cannot necessarily expect to find such a lin-
ear association. Whether there is utility in monitor-
ing antibodies to CENP-F in patients who have tested 
positive remains to be determined. There have been no 
reports of patients having CENP-F positivity reverting 
to negative, and there is insufficient data on the semi 
quantitative and quantitative measures in individual 
patients over time. It is difficult to determine the future 
risk of malignancy in our patient, and although the 
positive predictive value of malignancy in those testing 
positive is 50  %, there is no literature on whether this 
risk changes after detection and treatment of an initial 
malignancy.
As mentioned above, there are theoretical benefits of 
FTI in patients with malignancies who express autoanti-
bodies to CENP-F. This is difficult to study directly due to 
small numbers of patients with CENP-F antibodies and 
FTIs currently being in trial, but it does raise the pros-
pect of this class of agent being effective in this popula-
tion. Our patient has already been exposed to multiple 
chemotherapeutic agents and it is foreseeable that she 
may require treatment for further malignancies. This may 
prove to be a useful option in the future.
Conclusion
This case highlights the association of CENP-F with 
malignancy, as well as deficiencies in our current knowl-
edge of autoantibodies targeting this antigen. The inci-
dence of these autoantibodies in patients with a BRCA1 
mutation is unknown. Further research into the preva-
lence in the BRCA1 population may provide useful infor-
mation for patient care as the target antigen is implicated 
in the mechanism of action of chemotherapeutic agents.
Consent
Written informed consent was obtained from the patient 
for publication of this Case report and any accompany-
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